Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $12,635.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd Petersen sold 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $25.27, for a total value of $12,635.00. Following the completion of the sale, the director owned 75,531 shares in the company, valued at approximately $1,908,668.37. This represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Amphastar Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ:AMPH opened at $24.03 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of 9.00 and a beta of 0.77. The company has a debt-to-equity ratio of 0.80, a quick ratio of 2.21 and a current ratio of 3.29. The company’s fifty day moving average is $26.23 and its 200-day moving average is $25.27. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $49.53.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million during the quarter, compared to the consensus estimate of $186.90 million. Amphastar Pharmaceuticals had a net margin of 18.64% and a return on equity of 20.76%. Equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AMPH has been the topic of several recent analyst reports. Bank of America boosted their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 26th. Piper Sandler reduced their price objective on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Zacks Research upgraded Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Needham & Company LLC reduced their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $31.20.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Millennium Management LLC raised its holdings in Amphastar Pharmaceuticals by 238.5% during the 1st quarter. Millennium Management LLC now owns 868,551 shares of the company’s stock worth $25,179,000 after buying an additional 611,995 shares during the period. TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 20.2% in the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company’s stock worth $64,130,000 after purchasing an additional 371,856 shares during the period. Royce & Associates LP increased its holdings in Amphastar Pharmaceuticals by 2,684.3% during the 1st quarter. Royce & Associates LP now owns 247,858 shares of the company’s stock worth $7,185,000 after purchasing an additional 238,956 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in shares of Amphastar Pharmaceuticals by 81.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 469,492 shares of the company’s stock valued at $10,780,000 after purchasing an additional 210,511 shares during the period. Finally, CX Institutional raised its stake in shares of Amphastar Pharmaceuticals by 220.5% in the 2nd quarter. CX Institutional now owns 263,283 shares of the company’s stock valued at $6,045,000 after purchasing an additional 181,136 shares during the period. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.